Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis

Company Overview

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: $7.86 to $8.15
• 50-Day Range: $5.75 to $8.10
• 52-Week Range: $4.09 to $15.92
• Volume: 123,692 shs
• Average Volume: 169,915 shs
• Market Capitalization: $173.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.50
• Consensus Rating: Moderate Buy

Enanta Pharmaceuticals Stock Analysis - MarketRank™

Enanta Pharmaceuticals scored higher than 76% of companies evaluated by MarketBeat, and ranked 256th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Enanta Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Enanta Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Enanta Pharmaceuticals are expected to decrease in the coming year, from ($4.65) to ($4.98) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Enanta Pharmaceuticals is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enanta Pharmaceuticals is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enanta Pharmaceuticals has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.19% of the float of Enanta Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Enanta Pharmaceuticals has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Enanta Pharmaceuticals has recently decreased by 3.20%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enanta Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Enanta Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -1.11

Percentage of Shares Shorted

12.19% of the float of Enanta Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Enanta Pharmaceuticals has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Enanta Pharmaceuticals has recently decreased by 3.20%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.56

News Sentiment

Enanta Pharmaceuticals has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.07 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Enanta Pharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for ENTA on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Enanta Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Enanta Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.89% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

94.99% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ENTA Stock Analysis - Frequently Asked Questions

How have ENTA shares performed this year?

Enanta Pharmaceuticals' stock was trading at $5.75 at the beginning of the year. Since then, ENTA shares have increased by 40.9% and is now trading at $8.10.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced its quarterly earnings data on Monday, May, 12th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.04) by $0.02. The biotechnology company had revenue of $14.93 million for the quarter, compared to the consensus estimate of $15.96 million. Enanta Pharmaceuticals had a negative net margin of 149.57% and a negative trailing twelve-month return on equity of 79.83%.

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' top institutional investors include Assenagon Asset Management S.A. (0.50%), CWM LLC (0.10%), Public Employees Retirement System of Ohio (0.06%) and Wealth Enhancement Advisory Services LLC (0.05%). Insiders that own company stock include Jay R Luly, Yat Sun Or, Paul J Mellett, Brendan Luu, Tara Lynn Kieffer, Scott T Rottinghaus and Terry Vance.
View institutional ownership trends.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enanta Pharmaceuticals investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/30/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ENTA
• CIK: 1177648
• Web: www.enanta.com
• Phone: (617) 607-0800
• Fax: 617-607-0530
• Employees: 160
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Enanta Pharmaceuticals: $18.50
• High Price Target: $24.00
• Low Price Target: $10.00
• Potential Upside/Downside: +128.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$116.04 million
• Net Margins: -149.57%
• Pretax Margin: -153.41%
• Return on Equity: -79.83%
• Return on Assets: -26.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.29
• Quick Ratio: 5.29

Sales & Book Value

• Annual Sales: $67.64 million
• Price / Sales: 2.56
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.08 per share
• Price / Book: 1.33

Miscellaneous

• Outstanding Shares: 21,380,000
• Free Float: 18,408,000
• Market Cap: $173.18 million
• Optionable: Optionable
• Beta: 0.84